• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Alumis Inc.

    7/24/24 4:06:45 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALMS alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001847367
    ESKER THERAPEUTICS, INC.
    FL2021-001, Inc.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    ALUMIS INC.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
       Over Five Years Ago
    X Within Last Five Years (Specify Year) 2021
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    ALUMIS INC.
    Street Address 1 Street Address 2
    280 EAST GRAND AVENUE
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    SOUTH SAN FRANCISCO CALIFORNIA 94080 650-231-6625

    3. Related Persons

    Last Name First Name Middle Name
    Babler Martin
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Bradley Mark
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Drappa Jorn
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Goldstein David M.
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hardiman Roy C.
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Schroer John R.
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Klein Sara
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Richardson Derrick
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Akkaraju Srinivas
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Colowick Alan B.
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Machado Patrick
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Srivastava Sapna B.
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Tananbaum James B.
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Yao Zhengbin
    Street Address 1 Street Address 2
    c/o Alumis Inc. 280 East Grand Avenue
    City State/Province/Country ZIP/PostalCode
    South San Francisco CALIFORNIA 94080
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-07-17    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $40,000,000 USD
    or    Indefinite
    Total Amount Sold $40,000,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    ALUMIS INC. /s/ Martin Babler Martin Babler CEO 2024-07-23

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $ALMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALMS

    DatePrice TargetRatingAnalyst
    1/21/2026$37.00Buy
    Chardan Capital Markets
    7/25/2025$17.00Overweight
    Wells Fargo
    6/10/2025$18.00Buy
    Guggenheim
    1/30/2025$32.00Outperform
    Oppenheimer
    10/31/2024$25.00Outperform
    Robert W. Baird
    10/17/2024$30.00Buy
    H.C. Wainwright
    7/23/2024Overweight
    Cantor Fitzgerald
    7/23/2024$29.00Outperform
    Leerink Partners
    More analyst ratings

    $ALMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $9,999,995 worth of shares (588,235 units at $17.00) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/13/26 6:20:06 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Foresite Labs, Llc bought $6,999,988 worth of shares (411,764 units at $17.00) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/12/26 9:59:02 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Foresite Capital Management Vi Llc bought $6,999,988 worth of shares (411,764 units at $17.00) (SEC Form 4)

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/12/26 9:58:40 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alumis to Participate in Upcoming February Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026February 11-12, 2026, New York, NYFireside chat: Thursday, February 12, 2026 at 9:00 am ET Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 25-26, 2026, VirtualPresentation: Thursday, February 26, 2026 at 3:20 pm ET To access the live webcasts please visit the "Events" page of the "Investors" section of the Alumis website. Web

    2/5/26 8:05:00 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share. The gross proceeds to Alumis from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $345.1 million. All of the shares in the offering were sold by Alumis

    1/9/26 4:05:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis Announces Pricing of Upsized Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Alumis from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300.0 million. All shares in the offering are being sold by Alumis. The offering is expected to close on January 9, 2026, subject to the satisfaction of cus

    1/7/26 10:52:42 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Alumis with a new price target

    Chardan Capital Markets initiated coverage of Alumis with a rating of Buy and set a new price target of $37.00

    1/21/26 8:54:19 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Alumis with a new price target

    Wells Fargo initiated coverage of Alumis with a rating of Overweight and set a new price target of $17.00

    7/25/25 9:06:03 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim resumed coverage on Alumis with a new price target

    Guggenheim resumed coverage of Alumis with a rating of Buy and set a new price target of $18.00

    6/10/25 8:07:01 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    SEC Filings

    View All

    SEC Form S-8 filed by Alumis Inc.

    S-8 - ALUMIS INC. (0001847367) (Filer)

    1/30/26 4:30:35 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Alumis Inc.

    SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)

    1/13/26 6:18:24 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Alumis Inc.

    SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)

    1/12/26 9:59:23 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer Pangali Sanam

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/28/26 7:22:01 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President, CEO and Chairman Babler Martin

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/28/26 7:21:02 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Business & Strategy Ofcr Hardiman Roy C.

    4 - ALUMIS INC. (0001847367) (Issuer)

    1/28/26 7:19:48 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Financials

    Live finance-specific insights

    View All

    Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

    – Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24, on average – – Envudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 program – – Alumis plans to submit a New Drug Application to the FDA in the second half of 2026 – – Conference call and webcast scheduled for 8:00 a.m. ET today – SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted

    1/6/26 7:00:00 AM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

    – Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Conference Call and Webcast DetailsAlumis' conference call and webcast to

    1/5/26 5:00:00 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

    Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

    2/6/25 4:15:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Alumis Inc.

    SC 13D - ALUMIS INC. (0001847367) (Subject)

    8/27/24 4:20:38 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Alumis Inc.

    SC 13G - ALUMIS INC. (0001847367) (Subject)

    7/11/24 4:30:21 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Alumis Inc.

    SC 13D - ALUMIS INC. (0001847367) (Subject)

    7/5/24 9:30:17 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care